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Purpose: Androgens stimulate the production of hypoxia-inducible factor (HIF1α) and ultimately vascular endothelial
growth factor (VEGF-A). Additionally, epithelial growth factor (EGF) mediates HIF1α production. Carbonic anhydrase IX
(CAIX) expression is associated with tumor cell hypoxia in a variety of malignancies. This study assesses the prognostic
relation between HIF1α, VEGF-A, EGF Receptor and CAIX expression by immunochemistry in diagnostic samples of
patients with intermediate- and high-risk localized prostate cancer treated with radiation therapy, with or without
androgen deprivation therapy (ADT).
Materials and methods: Between 1994 and 2004, 103 prostate cancer patients (mean age, 68.7 ± 6.2), with prostate
cancer (mean PSA, 13.3 ± 3.7), were treated with radiation therapy (RT, median dose, 74 Gy). Fifty seven (55.3%)
patients received ADT (median duration, 6 months; range, 0 – 24). Median follow-up was 97.6 months (range,
5.9 – 206.8).
Results: Higher EGFR expression was significantly (p=0.04) correlated with higher Gleason scores. On univariate
analysis, HIF1α nuclear expression was a significant (p= 0.02) prognostic factor for biological progression-free survival
(bPFS). A trend towards significance (p=0.05) was observed with EGFR expression and bPFS. On multivariate analysis,
low HIF1α nuclear (p=0.01) and high EGFR (p= 0.04) expression remained significant adverse prognostic factors.
Conclusions: Our study suggests that high nuclear expression of HIF1α and low EGFR expression in diagnostic
biopsies of prostate cancer patients treated with RT ±ADT is associated with a good prognosis.Background
It has been recognized that cancer-stromal cell interac-
tions is a major player of malignant behavior in cancer.
More specifically, hypoxia may trigger vascular endothe-
lial growth factor (VEGF) expression via the transcription
complex of hypoxia-inducible factor HIF1α. Hypoxia and
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reproduction in any medium, provided the orprostate cancer progression, as VEGF and HIF1α is
increased in prostate cancer, when compared to benign
prostatic hypertrophy [1,2]. Additionally, a direct link
between androgen receptors and pro-angiogenic factors
may exist, as HIF1α, via epithelial growth factor (EGF),
expression is increased with androgens [3] and decreased
in prostatectomy specimen treated with pre-operative
androgen deprivation therapy (ADT) [4]. The carbonic
anhydrase IX (CAIX) gene is a target of HIF1α and is
up-regulated in hypoxia [5]. Likewise, it has been shown
that androgen deprivation in cell culture decreases
VEGF mRNA expression [6] and castration in rodents’Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Intermediate- and high-risk prostate cancer
patient’s and treatment characteristics
Number of patients 103
Age (years)
Median 69.1























PSA prostatic-specific antigen ; ADT anti-androgen deprivation therapy.
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xenografts [7]. The prognostic significance of EGF-
receptor (EGFR), HIF1α and VEGF-A in prostate can-
cer is somewhat disputed. Some series have shown a
negative outcome in patients with pre-treatment VEGF
expression [8], whilst other studies have suggested an
improved outcome in patients undergoing radical
prostatectomy [4].
Given the lack of strong prognostic evidence regarding
these markers in patients who may benefit from dose
escalation RT, we analyzed tumor expression of EGFR,
HIF 1α, VEGF-A and CAIX with respect to freedom
from biochemical progression in men with intermediate-
and high-risk prostate cancer treated with RT, with or
without ADT.
Methods
Between 1994 and 2004, 103 patients with clinically
localized (according to the 2002 TNM American Joint
Committee on Cancer staging system: cT1c – cT2b) or
locally advanced (cT3a – cT4) non-metastatic prostate
cancer with diagnostic samples with histological proven
adenocarcinoma were indentified in our institutional
database. All patients underwent bone scintigraphy and
endo-rectal MRI staging prior to radiation therapy (RT).
All patients were classified as having intermediate-risk
disease (n= 53; 51.5%) or high risk (n= 50; 48.5%), as
defined by d’Amico et al. criteria (Table 1). Six months
ADT was administered to 57 (55.3%) patients (Table 1).
RT (mean dose, 75.1 ± 2.8 Gy; Table 1) was delivered
concomitantly after 3 months of ADT for those receiv-
ing ADT or immediately for those not receiving ADT.
Patients were followed with 6-monthly PSA tests. This
study was approved by the institutional ethic committee
(NAC 08-076R) and complied to the Helsinki declar-
ation. Prior to study initiation, written, informed consent
to perform this analysis was obtained from all patients.
The mean duration of the follow up time was
96.4 ± 33.7 months. No patients were lost to follow-up.
Immunochemistry
All tissues obtained by prostate biopsy or transurethral
resection of the prostate were formalin-fixed or Duboscq-
Brazil-fixed and paraffin embedded. The hematoxylin-eosin
stained sections were reviewed to confirm the diagnosis
and only sections showing typical Gleason score were
selected. For immunohistochemistry (IHC), section 4 μm
from one representative block of each patient were depar-
affinized, rehydrated, and then submitted to IHC analysis
as follow.
HIF1α After boiling with a pressure cooker in Tris-
EDTA pH:9.0 buffer for 3 min, sections were incubated
in DAKO autostainer with the monoclonal mouse HIF1αantibody clone H1alpha67 (NB100-123, NOVUS Biologi-
cals) diluted 1/1000 and stained with CSA-II-Biotin-free
Tyramide Signal Amplification System (K1497, DAKO).
Renal clear cell carcinoma served as a positive control.
Primary antibody was substituted with mouse IgG2b for
negative control.
VEGF-A After boiling with a pressure cooker in citrate
pH:6.0 buffer for 3 min, sections were incubated in
DAKO autostainer with the monoclonal mouse VEGF-A
antibody clone VG1 (18–7328, ZYMED Laboratories)
diluted 1/50 and stained with stained with EnVision anti
mouse/rabbit (K5007, DAKO). Renal clear cell carcin-
oma served as a positive control. Primary antibody was
substituted with mouse IgG1 for negative control.
EGFR After proteinase K (S3020, DAKO) digestion for
30 min, only for formalin-fixed tissu, sections were
incubated with the monoclonal mouse EGFR antibody
clone 31 G7 (28–0005, ZYMED Laboratories) diluted 1/
20 and stained with EnVision anti mouse/rabbit (K5007,
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trol. Primary antibody was substituted with mouse IgG1
for negative control.
CAIX After boiling with a pressure cooker in citrate
pH:6.0 buffer for 3 min, sections were incubated with
the polyclonal rabbit CA-IX antibody (NB100-417,
NOVUS Biologicals) diluted 1/1500 and stained with En-
Vision anti mouse/rabbit (K5007, DAKO). Renal clear
cell carcinoma served as a positive control. Primary anti-
body was substituted with nonimmune rabbit immuno-
globulin (DAKO) for negative control. Visualization of
the primary antibody was achieved using diaminoden-
zine as chromogen and section were lightly counter-
stained with hematoxylin.
Quantification
The percentage and intensity of positively nuclear and
intensity of cytoplasmic staining in tumor cells were
evaluated. HIF1α expression was assessed in tumor cells
using a modified previously published semiquantitative
scoring [9]. The immunohistochemical results for HIF1α
were classified as follow for nuclear and cytoplasmic
percentage staining: 0, no staining; 1, less than 1%
of cells; 2, 1–10%; 3, 10–50%; 4, more than 50%; for
nuclear and cytoplasmic intensity staining [8]: 0, no
staining; 1, weak staining; 2, moderate staining; 3, strong
staining. The percentage and intensity nuclear and cyto-
plasmic intensity scores were added together to give a
final immunoreactive score (IRS) of 0 to 10. HIF1α was
categorized as low HIF1α= ≤ 50% cells staining and high
HIF1α = > 50% cells staining.
VEGF-A expression was assessed in tumor cells using
a previously published semiquantitative scoring in
prostate tissue [10]. The percentage of positively tumor
cells was evaluated and the VEGF-A staining inten-
sity was assessed. The percentage and intensity scores
were added together to give a final immunoreactive
score (IRS) of 0 to 8. VEGF-A IRS scores were categor-
ized as low VEGF-A= IRS score < 5, high VEGF-A= IRS
score >5.
EGFR expression was assessed in tumor cells using a
previously published semiquantitative scoring in prostate
tissue [11]. EGFR expression was assessed in tumor cells
and only membranous EGFR staining was considered.
The percentage of positive tumor cells was estimated as
follow: 0, no membranous staining, 1, <30% of cells; 2,
30–50% of cells; 3, >50% of cells. The staining intensity
was scored as follow: 0, no staining; 1, weak staining; 2,
moderate staining; 3, strong staining. Tumor were sub-
sequently categorized as negative (no membranous
staining), strongly positive (>50% with moderate inten-
sity or >30% of cells with strong intensity) or weakly
positive if not reaching the criteria selected above.CA-IX expression was assessed in tumor cells using
a previously published score [12]. Only membranous
CA-IX staining was considered. Immunostaining of
>10% of tumor cells was necessary to be positive.
Diagnostic biopsies were assessed by a two prostate-
cancer histopathologist blinded to patient outcome.
Statistical considerations
Biochemical progression-free survival (bPFS), cancer-
specific (CSS) and overall survival (OS) were calculated
from the date of RT using Kaplan-Meier estimates. The
events were death (all causes of death included) for OS,
death from prostate cancer for CSS and biochemical
PSA failure or death for bPFS. Biochemical failure was
defined by use of the Houston criteria. Patients free from
biochemical failure were censored on the date of their
last PSA test. Proportions were compared using the Chi-
square test for values > 5 and Fisher’s exact test for
values ≤ 5. Differences between groups were assessed
using the log-rank test. The log-rank test was used to
compare different survival functions according to the
HIF1α, EGFR and VEGF-A expression. Multivariate
cause-specific Cox models that accounted for competing
risks were fit separately for prostate cancer patients. The
proportional hazards assumption was tested using scaled
Schoenfeld residuals, with visual inspection of the log
minus log plots. Predictors included PSA, Gleason, age,
HIF1α, EGFR and VEGF-A expression. All statistical
tests were two sided, with alpha levels lower than .05
considered statistically significant.
Results
Median follow-up was 8.1 years and 27 (26.2%) patients
died, 8 of prostate cancer. The estimated 8-year CSS and
OS was 70.4% (95%CI: 47.3 – 93.5) and 81.4 (95%CI:
73.2 –89.4), respectively. Twenty-nine (28.2%) patients
developed biochemical failure. The estimated 8-year
bPFS was 73.4% (95%CI: 64.0 – 82.8). No CAIX expres-
sion was observed in this series, whereas the majority of
tumors had a strong HIF1α and VEGF-A expression
(Table 2).
A significant correlation was noted between higher
EGFR expression and higher Gleason score (p= 0.04).
No, weak and strong EGFR expression was observed in
30 (50.0%), 16 (26.7) and 14 (23.3%) in tumor with Glea-
son scores < 7, respectively. The corresponding values
were 11 (26.2%), 19 (45.2%) and 12 (28.6%) in tumor
with Gleason scores ≥ 7, respectively. A trend toward
significance was observed between higher EGFR expres-
sion and risk categories (p= 0.07). No, weak and strong
EGFR expression was observed in 24 (50.0%), 11 (22.9%)
and 13 (27.1%) in intermediate-risk tumors. The cor-
responding values were 18 (32.7%), 24 (43.6%) and 13
(23.6%) in high-risk tumors. Conversely, no significant
Table 2 Distribution of EGFR, HIF1α,VEGF-A and CAIX for








No staining 9 (8.7)
< 10% 3 (2.9)
10 – 50% 9 (8.7)








RT radiotherapy; ADT anti-androgen deprivation therapy; NA not assessable.
Table 3 Univariate analysis of biochemical progression-
free survival
Parameter 8-year bPFS [%](95%CI) p
PSA 0.41

















≤ 61 years 70.1
(59.7–80.5)












PSA prostatic-specific antigen, ADT anti-androgen deprivation therapy.
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PSA (p= 0.27). No significant correlation was also
observed between HIF1α and VEGF-A expression and
any of the baseline clinical characteristics (Gleason, PSA
and risk category).
Univariate analysis of the parameters in relation to
biochemical control is detailed in Table 3. High expres-
sion of HIF1α was associated with a significant increase
in bPFS (p= 0.019; Table 3). The 8-year bPFS was 75.5%
[95%CI: 65.1 – 85.9] and 64.6% [95%CI: 43.0 – 86.2]
for patients with > 50% and ≤ 50% nuclear expression,
respectively (Figure 1). A statistical trend was observed
with expression of EGFR: strong IHC expression was a
predictor of a shorter time to biological failure (p= 0.05,
Table 3; Figure 1). The 8-year bPFS was 63.7% [95%CI:
50.8 – 76.6], and 90.4% [95%CI: 81.4 – 99.4] for patients
with strong/weak and no EGFR staining, respectively
(Figure 1). VEGF-A was however not correlated with
biological outcome (p= 0.92; Table 3). The 8-year bPFS
was 70.5% [95%CI: 51.7 – 89.3] and 74.4% [95%CI: 63.6
– 85.2] for patients with low and high VEGF-A staining,
respectively. PSA (p= 0.41), ADT (p= 0.22), Gleason
(p= 0.50), Risk category (p= 0.58), age (p= 0.13) and
dose (p= 0.78) were not significant predictors of bPFS
(Table 3). On multivariate analysis, low HIF1α (p= 0.01)
and high EGFR (p= 0.04) expression remained signifi-
cant adverse prognostic factors (Table 4).
ADT administration did not improve the biological
outcome of patients with low or high HIF1α expression
(Table 5).Discussion
In our study, approximately three quarters of all prostate
tumors strongly expressed HIF1α, and VEGF-A (Table 2),
a number that is similar to the figures reported by others
in prostate cancer [8]. Unlike locally-advanced prostate
cancer, strong EGFR expression was observed in one
quarter of the studied patients, as reported by other
investigators in early stage prostate cancer [13].
High expression of HIF1α was unexpectedly asso-
ciated with an improved biochemical survival (Table 3;
Figure 1). These findings contrast with published results
suggesting that low expression of this transcription fac-
tor is associated with better clonogenic survival in breast
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Figure 1 Biological progression-free survival as a function of HIF1α (A), EGFR (B) and VEGF-A (C) expression in 103 intermediate- and
high-risk prostate cancer.
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cancers are not unequivocal [16]. In a head and neck
(H&N) series, high expression of HIF1α in 79 surgically
treated patients with squamous cell carcinoma was sig-
nificantly associated with improved disease-free and
overall survival in multivariate analysis [17]. Likewise,
HIF1α expression was assessed in 85 patients with early
stage T1−2 H&N squamous cell carcinoma treated with
surgery alone by IHC on tissue micro arrays [18]. High
expression of HIF1α was associated with an improved 5-
year disease-free and overall survival in multivariate ana-
lysis. Of note, the transcription of the HIF1α-subunit is
regulated by two synergistic mechanisms. First, PHD
enzymes catalyze the hydroxylation of two prolin resi-
dues in the oxygen degradation-dependant domain of
this subunit. Consequently, HIF1α will be recognized by
von Hippel-Lindau protein that will allow degradation
by the proteosome. The second mechanism involves
Factor Inhibiting Hypoxia-inducible factor 1 (FIH-1).
Under normoxic conditions, FIH-1 hydroxylates an
aspirigine residue in the C-terminal portion of the two
HIF1α isoforms. This modification prevents the inter-
action of HIF1α C-terminal domain with the transcrip-
tional co-activator p300, thus decreasing HIF1α
transcriptional activity and increasing HIF1α expression.
Interestingly, nuclear FIH-1 was associated with afavorable biochemical survival in a recent prostatectomy
series [19]. These data suggests that HIF1α may be asso-
ciated with a better biochemical outcome in prostate
cancer patients, although the r-value of the FIH-1/HIF1α
correlation was not given by the English authors [19].
Noteworthy, HIF1α was not prognostic in prostate can-
cer patients included in a French dose escalation study
[20] and an US prostatectomy series [4] using IHC and
gene expression, respectively.
The reasons for these discrepant observations are un-
clear. Notwithstanding the issue of hypoxia and radio-re-
sistance, the potential phenotypic aggressiveness of
HIF1α-negative tumor cells has been documented in
series [21]. HIF1α is known to play a role in promoting
tumor cell’s apoptosis. In a series of embryonic stem
cells model the proliferation HIF1α +/+ knockout cells
was reduced or delayed in hypoxic conditions [21]. Con-
versely, growth of HIF1α −/− knockout embryonic cells
was not retarded but was increased, possibly because of
decreased hypoxia-induced apoptosis and increased
stress-induced proliferation [21]. It may well be that
these HIF1α-negative cells may loses their ability to
undergo apoptosis, at a distance from blood vessels, re-
ducing thus their critical dependence on vascular supply.
Our results contrast radically with those published by
the Royal Marsden group (RMH) [8]. In this study, the
Table 4 Multivariate analysis for biochemical progression-free survival
Parameter HR(95%CI) p HR(95%CI) p HR(95%CI) p
PSA 0.19 0.24 0.22
≤ 15 ng/ml 1.0 1.0 1.0
>15 ng/ml 0.55(0.23–1.33) 0.59(0.25–1.42) 0.57(0.24–1.38)
Gleason 0.91 0.90 0.74
< 7 1.0 1.0 1.0
≥ 7 1.04(0.48–2.27) 0.95(0.44–2.07) 1.14(0.53–2.45)
Age 0.16 0.17 0.16
≤61 years 1.0 1.0 1.0
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were entered into two sequential dose-escalation trials
(64 Gy vs. 74 Gy) with ADT. The same biochemical fail-
ure definition was used in both studies. Patients in the
RMH study has somehow more favorable characteristics
when compared to those in the present study (T2 59%
vs. 23%; Gleason < 7, 74% vs. 58%; median PSA, 11.5 vs.
13.1 ng/ml). Possible explanation for these contradic-
tory findings may include imbalances between the twoTable 5 Bio-chemical Progression-free survival in patients
treated with exclusive RT and combined RT and ADT as a
function of HIF1α, EGFR and VEGF-A expression





Low-HIF1α † 63.6[40.7 – 99.5] 70.0[46.7 – 100.0] 0.46
High-HIF1α { 68.0[52.5 – 88.2] 80.7[69.4 – 91.9] 0.30
No EGFR 82.2[67.8 – 99.7] 100.0[NA] 0.36
Weak EGFR ** 37.3[13.8 – 100.0] 74.1[58.1 – 94.6] 0.15
Strong EGFR * 62.5[38.9 – 100.0] 61.5[40.0 – 94.6] 0.65
low VEGF-A } 68.6[44.5 – 100.0] 74.8[56.1 – 99.7] 0.33
high VEGF-A } 67.8[45.9 – 84.2] 80.2[68.0 – 94.7] 0.45




* > 50% with moderate intensity or >30% of cells with strong intensity.
**Not reaching the above criteria.
low VEGF-A = IRS score < 5, high VEGF-A = IRS score >5.cohorts (the biochemical progression rate was 38% vs.
28% in the RMH and present series, respectively) or
the immunoreactivity assessment methodology. In the
RMH study, HIF1α was assessed in terms of cytoplasmic
staining. We found HIF1α-nuclear only expression in
our study for this nuclear transcription factor (Table 2).
Unlike the RMH staining methodology, we used double
IHC staining method, as detailed by Vaughan et al.
[22]. Alternatively, more advanced prostate tumors may
express differentially HIF1α. HIF1α mRNA gene expres-
sion was significantly unregulated in blood samples of
localized prostate cancer patients, when compared to
individuals with no malignancies or those with more
advanced tumors in a recent prospective study [23].
Strong EGFR expression was associated (p= 0.05) with
a decrease in bPFS (Table 3; Figure 1). The prognostic
relevance of EGFR expression was also observed in a
recent Italian series of prostate cancer patients [13]. The
observed median time to biochemical failure in this
series was 104 and 30 months in EGFR <50% and
≥50% tumors, respectively (HR, 2.5; p= 0.02). EGFR
expression may have a role in the development of pros-
tate cancer [24]. EGFR is down regulated at the tran-
scriptional level by androgens in normal prostate tissue
but up-regulated in prostate malignancy, especially in
androgen-independent prostate cancer. Di Lorenzo
et al., reporting on 76 patients with androgen-dependent
and -independent prostate cancer, observed 41%, 76%
and 100% EGFR expression in radical prostatectomy,
Weber et al. Radiation Oncology 2012, 7:66 Page 7 of 8
http://www.ro-journal.com/content/7/1/66hormone-sensitive and hormone-refractory metastatic
patients, respectively [24]. We have observed a signifi-
cant association between EGFR expression and higher
Gleason scores (p=0.04). These results may also be in
keeping with other series [24]. It remains to be demon-
strated if EGFR therapeutic targeting may optimize patient
outcome [25]. EGFR prognostication needs to be more
fully assessed in the framework of prospective studies.
The expression of the angiogenic factor VEGF-A, a
soluble growth factor acting as a specific endothelial
mitogen, and its receptor may be an important factor in
the prostate carcinogenesis. In our series, high-VEGF-A
expression was usually not associated with biochemical
failure (Table 3, Figure 1). The absence of a significant
correlation observed in our study may be due to the
small sample size, that may have limited the statistical
power to detect associations between VEGF-A expres-
sion and biochemical outcome, or to the diffuse and
multifocal IHC-expression pattern in prostate cancer
that may render the quantification of this glycoprotein
somewhat difficult [26,27].
CAIX is normally expressed in epithelial cells of the
intestines and stomach but may be expressed when
tumor cell hypoxia occurs in malignancies. It is
expressed in carcinomas derived from cells not expres-
sing this membrane-bound glycoprotein, such as those
observed in lung, breast or kidney and may be associated
with a negative prognosis in these tumours. Prostate
cancer cell line may express CAIX in strong hypoxic
conditions. In our series, none of the prostate cancer
cells expressed CAIX in diagnostic samples and could
thus not be considered strongly hypoxic (Table 2). The
NB100-417 antibody, used in this series, has been asso-
ciated with false positive but not false negative IHC
results. As such, prostate cancer cells in core our histo-
logical samples were not hypoxic.
We could not demonstrate an impact on biochemical
outcome in patients with unfavorable (i.e. tumors low
HIF1α and/or high EGFR immunoreactivity) tumors
treated with RT±ADT (Table 5). Androgen deprivation
improves tumor oxygenation and may thus increase the
efficacy of RT in patients with unfavorable prognosis.
Small patient numbers complicate the analysis of these
findings. The number of patients in the low-HIF1α
group receiving or not receiving ADT was 10 and 11, re-
spectively (data not shown). In our series, a better 8-year
bPFS was observed with low HIF1α immunoreactivity
treated with ADT when compared to RT alone. Future
efforts should be directed toward the understanding of
the role of these parameters in selecting treatment for
intermediate- and high-risk prostate cancer patients in
the frame of prospective studies.
This study has potential limitations inherent in all
retrospective analyses, including uncontrolled patientsselection into the different treatment groups. Major lim-
itations of this study include but are not limited to the
IHC evaluation in a limited sample of diagnostic tissue
that may not reflect the intrapatient heterogeneity of
tissue marker expression and the limited overall number
of patients. To our knowledge, the present report is
however the first to report a positive association between
biochemical outcome and high-HIF1α immunoreactivity
in intermediate- and high-risk prostate cancer patients
treated with RT.
Conclusions
In summary, HIF1α and VEGF-A was frequently expressed
in prostate cancer cells. HIF1α possibly non-hypoxia
related expression in diagnostic biopsies was associated
with an improved biochemical survival. EGFR immunor-
eactivity was associated with poor outcome.
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